Is Buying Avenue Therapeutics Inc (NASDAQ:ATXI) Here Good Idea?

November 10, 2018 - By Kristen Paramore

The stock of Avenue Therapeutics Inc (NASDAQ:ATXI) registered a decrease of 51.15% in short interest. ATXI’s total short interest was 12,700 shares in November as published by FINRA. Its down 51.15% from 26,000 shares, reported previously. With 6,000 shares average volume, it will take short sellers 2 days to cover their ATXI’s short positions. The short interest to Avenue Therapeutics Inc’s float is 0.22%.

The stock increased 1.21% or $0.05 during the last trading session, reaching $4.19. About 24,444 shares traded. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has declined 45.48% since November 10, 2017 and is downtrending. It has underperformed by 61.10% the S&P500.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $44.22 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: which released: “44 Biggest Movers From Yesterday” on October 15, 2018, also with their article: “50 Biggest Movers From Yesterday” published on October 19, 2018, published: “Avenue Therapeutics (NASDAQ:ATXI) CEO and President Lucy Lu, MD, has a Replacement for Medical Opiods” on October 15, 2018. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: and their article: “20 Stocks Moving In Friday’s Pre-Market Session” published on October 12, 2018 as well as‘s news article titled: “41 Stocks Moving In Friday’s Mid-Day Session” with publication date: October 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.